Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis - Université d'Angers Accéder directement au contenu
Article Dans Une Revue Respiratory Research Année : 2020

Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis

Résumé

BACKGROUND: Nintedanib is an approved therapy for idiopathic pulmonary fibrosis (IPF). Some patients treated with nintedanib experience weight loss. Exploratory data suggest that low body mass index or weight loss are associated with worse outcomes in patients with IPF. We investigated whether BMI at baseline or weight loss over 52 weeks was associated with FVC decline, or influenced the effect of nintedanib, in patients with IPF.METHODS: Using pooled data from the two INPULSIS trials, we analysed the rate of decline in FVC (mL/yr) over 52 weeks in patients treated with nintedanib and placebo in subgroups by baseline BMI (< 25; ≥25 to < 30; ≥30 kg/m(2)) and by weight loss over 52 weeks (≤5; > 5%) using random coefficient regression.RESULTS: In the placebo group, the mean rate of FVC decline over 52 weeks was numerically greater in patients with lower baseline BMI (- 283.3 [SE 22.4], - 207.9 [20.9] and - 104.5 [21.4] in patients with BMI < 25 kg/m(2), ≥25 to < 30 kg/m(2) and ≥ 30 kg/m(2), respectively). Nintedanib reduced the rate of FVC decline versus placebo in all subgroups by BMI, with a consistent treatment effect across subgroups (interaction p = 0.31). In the placebo group, the mean rate of FVC decline was numerically greater in patients with > 5% than ≤5% weight loss over 52 weeks (- 312.7 [SE 32.2] versus - 199.5 [SE 14.4] mL/year). Nintedanib reduced the rate of FVC decline versus placebo in both subgroups by weight loss, with a greater treatment effect in patients with > 5% weight loss (interaction p = 0.0008). The adverse event profile of nintedanib was similar across subgroups.CONCLUSIONS: In patients with IPF, lower BMI and weight loss may be associated with faster decline in FVC. Nintedanib reduces the rate of FVC decline both in patients who lose weight on treatment and those who do not. TRIAL REGISTRATION: ClinicalTrials.gov ; Nos. NCT01335464 and NCT01335477 ; URL: www.clinicaltrials.gov .
Fichier principal
Vignette du fichier
s12931-020-01528-4 (1.05 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03038325 , version 1 (28-05-2021)

Licence

Paternité

Identifiants

Citer

Stéphane Jouneau, Bruno Crestani, Ronan Thibault, Mathieu Lederlin, Laurent Vernhet, et al.. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. Respiratory Research, 2020, 21 (1), pp.312. ⟨10.1186/s12931-020-01528-4⟩. ⟨hal-03038325⟩
93 Consultations
22 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More